Abstract:Pallam Gopichand, 1 Girija Agarwal, 2 Mailan Natarajan, 1 Jharna Mandal, 1 Surendran Deepanjali, 3 Sreejith Parameswaran, 4 LN Dorairajan 5 1 Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India; 2 Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India; 3 Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India; 4 Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India; 5 Department of Urology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, India Background: Rising rates of resistance to antimicrobial drugs among Enterobacteriaceae limit the choice of therapeutic agents to treat urinary tract infections. In this context we assessed the in-vitro effect of fosfomycin against extended-spectrum beta-lactamases, AmpC beta-lactamases and carbapenemase-producing strains of Escherichia coli, Klebsiella pneumoniae, Enterobacter spp, and P seudomonas aeruginosa isolated from the patients with urinary tract infection (UTI) and also studied the effect of fosfomycin on their biofilm formation. Materials and methods: A total of 326 multidrug-resistant (MDR) isolates comprising of Escherichia coli, Klebsiella pneumoniae, Enterobacter spp, and P seudomonas aeruginosa from the urine samples of the patients with a diagnosis of UTI were included in the study. MIC 50 and MIC 90 were detected by agar dilution method and the capacity to form biofilm in the presence of fosfomycin by these MDR isolates was assessed by the tissue culture plate method. Results: The MIC50 for meropenem (0.5 μgm/mL) and nitrofurantoin (32 μgm/mL) was within the susceptible range only for E. coli . Fosfomycin was the only antibiotic that inhibited 100% E.coli , 70% Klebsiella spp, and 50% Pseudomonas spp and 40% Enterobacter spp which included the extended-spectrum beta-lactamases producers. It showed a similar effect on carbapenemase producers and AmpC producers. Fosfomycin disrupted biofilm in 67% (n=141) E.coli , 74% (n=50) Klebsiella spp, 88% (n=27) Pseudomonas spp and 36% (n=23) Enterobacter spp at 24 hrs of incubation with a concentration of 2 fold dilution lower than that of the MIC. Conclusion : Fosfomycin showed a good inhibitory effect on the biofilms produced by the MDR organisms studied here. Keywords: fosfomycin, MDR, UTI, MIC, biofilm

Using fosfomycin to prevent infection following ureterorenoscopy in response to shortage of cephalosporins: a retrospective preliminary study

Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study

The Efficacy of Fosfomycin as Antibiotic Prophylaxis for Transrectal Prostate Biopsy and Impact on Lower Urinary Tract Symptom After Biopsy: A Prospective Study

Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study

Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria

In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections

[Antibacterial prophylaxis with fosfomycin at the time of the urethral catheter removal after radical prostatectomy (prospective randomized trial)]

Antimicrobial Susceptibilities of Clinical Bacterial Isolates from Urinary Tract Infections to Fosfomycin and Comparator Antibiotics Determined by Agar Dilution Method and Automated Micro Broth Dilution

Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis

Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis

In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance

Emerging Resistance among Uropathogens: Is Fosfomycin Revival the Best Hope?

In Vitro Susceptibility of Escherichia Coli Strains Isolated from Urine Samples Obtained in Mainland China to Fosfomycin Trometamol and Other Antibiotics: a 9-Year Surveillance Study (2004–2012)

Letter to the Editor for the Article “antibiotics Efficacy in Clinical and Microbiological Cure of Uncomplicated Urinary Tract Infection: a Systematic Review and Network Meta-Analysis”

Efficacy and safety of fosfomycin trometamol for urinary tract infection: a Meta-analysis

Comparison of ciprofloxacin versus fosfomycin versus fosfomycin plus trimethoprim/sulfamethoxazole for preventing infections after transrectal prostate biopsy

Antibiotic Resistance Patterns Among Uropathogens in Female Outpatients Affected by Uncomplicated Cystitis: Focus on Fosfomycin Trometamol

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial

Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections

The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study

Amoxicillin/Clavulanic Acid in Transrectal Biopsy of the Prostate—An Alternative in Times of Ciprofloxacin Obsolescence and Fosfomycin Limitation?